Compare ADMA & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADMA | STVN |
|---|---|---|
| Founded | 2004 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Containers/Packaging |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.2B |
| IPO Year | 2012 | 2021 |
| Metric | ADMA | STVN |
|---|---|---|
| Price | $16.31 | $15.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $32.00 | $25.67 |
| AVG Volume (30 Days) | ★ 3.1M | 524.4K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.40% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $42,219,783.00 | N/A |
| Revenue This Year | $27.46 | $10.26 |
| Revenue Next Year | $21.11 | $10.02 |
| P/E Ratio | ★ $26.37 | $27.15 |
| Revenue Growth | ★ 43.85 | N/A |
| 52 Week Low | $13.76 | $13.91 |
| 52 Week High | $25.67 | $28.00 |
| Indicator | ADMA | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 53.14 | 47.06 |
| Support Level | $15.35 | $14.03 |
| Resistance Level | $17.53 | $17.14 |
| Average True Range (ATR) | 0.82 | 0.83 |
| MACD | 0.08 | 0.08 |
| Stochastic Oscillator | 68.97 | 38.17 |
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.